Investors Are Waking Up To Citius Pharmaceuticals Inc (NASDAQ: CTXR) After Losing -18.34% Over The Past 12 Months

Citius Pharmaceuticals Inc (NASDAQ:CTXR) currently has a daily average trading volume of 2.27M but it saw 2258329 shares traded in last market. With a market cap of 168.19M USD, the company’s current market price of $0.93 came rising about 0.31 while comparing to the previous closing price of $0.93. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.17 and as low as $0.48.

Taking a look at 20-day trading activity of Citius Pharmaceuticals Inc (CTXR) gives us an average price of $0.7258, while its current price level is -20.44% below from 52-week high level whereas it is 93.94% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.6797 while that of 200 days or SMA-200 reads an average of $0.7372. A closer look into the stock’s movement over the week reveals that its volatility is standing at 11.84% during that period while stretching the period over a month that decreases to 11.61%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 69.46 which implies that the stock is in neutral territory.

The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Maxim Group which initiated the stock as “Buy” in its note to investors issued on November 30, 2021, recommending a price target of $4 for it.

Over the week, CTXR’s stock price is moving 12.62% up while it is 38.94% when we observe its performance for the past one month. Year-to-date it is 23.05% up and over the past year, the stock is showing a downside performance of -18.34%.

Currently, Citius Pharmaceuticals Inc’s total number of outstanding shares is 180.67M. Company’s return on investment (ROI) stands at -46.97% and return on equity (ROE) at -42.44%. It has a 13.96 of forward P/E ratio. Stock’s beta reads 1.62. Stock has a price to book (P/B) ratio of 1.87. Its return on asset (ROA) is -37.14% on average.